Engineering lymphocyte subsets: tools, trials and tribulations

Cell-based therapies with various lymphocyte subsets hold promise for the treatment of several diseases, including cancer and disease resulting from inflammation and infection. The ability to genetically engineer lymphocyte subsets has the potential to improve the natural immune response and correct impaired immunity. In this Review we focus on the lymphocyte subsets that have been modified genetically or by other means for therapeutic benefit, on the technologies used to engineer lymphocytes and on the latest progress and hurdles in translating these technologies to the clinic.

[1]  T. Eberlein,et al.  Induction of Antigen-Specific CTL by Recombinant HIV Trans-Activating Fusion Protein-Pulsed Human Monocyte-Derived Dendritic Cells 1 , 2003, The Journal of Immunology.

[2]  F. Bushman.  Retroviral integration and human gene therapy. , 2007, The Journal of clinical investigation.

[3]  T. Friedmann.  A brief history of gene therapy , 1992, Nature Genetics.

[4]  James L Riley,et al.  Human T regulatory cell therapy: take a billion or so and call me in the morning. , 2009, Immunity.

[5]  C. Macken,et al.  A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  S. Dzekunov,et al.  A non-viral gene delivery system designed for clinical use. , 2003, Cytotherapy.

[7]  K. Cornetta,et al.  Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. , 2007, Blood.

[8]  M. Kalos,et al.  Transfer of Specificity for Human Immunodeficiency Virus Type 1 into Primary Human T Lymphocytes by Introduction of T-Cell Receptor Genes , 2000, Journal of Virology.

[9]  B. Fehse,et al.  Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. , 2006, Human gene therapy.

[10]  I. Pastan,et al.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains , 2009, Proceedings of the National Academy of Sciences.

[11]  T. Schumacher,et al.  Functional Human Antigen-Specific T Cells Produced In Vitro Using Retroviral T Cell Receptor Transfer into Hematopoietic Progenitors1 , 2007, The Journal of Immunology.

[12]  J. Melenhorst,et al.  An APC for every occasion: induction and expansion of human Ag-specific CD4 and CD8 T cells using cellular and non-cellular APC. , 2004, Cytotherapy.

[13]  O. Singer,et al.  Use of Amplicon-6 Vectors Derived from Human Herpesvirus 6 for Efficient Expression of Membrane-Associated and -Secreted Proteins in T Cells , 2004, Journal of Virology.

[14]  W. Smiddy.  Economic implications of current age-related macular degeneration treatments. , 2009, Ophthalmology.

[15]  Hans-Peter Kiem,et al.  Foamy virus vector integration sites in normal human cells , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[17]  Dana Carroll,et al.  Gene targeting using zinc finger nucleases , 2005, Nature Biotechnology.

[18]  Hao Liu,et al.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.

[19]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[20]  Mike Gough,et al.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.

[21]  M. Tykocinski,et al.  New designs for cancer vaccine and artificial veto cells , 2003, Immunologic research.

[22]  Mark Isalan,et al.  Zinc-finger protein-targeted gene regulation: Genomewide single-gene specificity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Bothwell,et al.  Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis , 2008, Proceedings of the National Academy of Sciences.

[24]  M. Merkenschlager,et al.  RNAi and chromatin in T cell development and function. , 2008, Current opinion in immunology.

[25]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[26]  M. Zöller,et al.  Characterization of Tumor Reactivity of Human Vγ9Vδ2 γδ T Cells In Vitro and in SCID Mice In Vivo1 , 2004, The Journal of Immunology.

[27]  P. Muranski,et al.  Adoptive immunotherapy of cancer using CD4(+) T cells. , 2009, Current opinion in immunology.

[28]  Jiang Zhu,et al.  Host-reactive CD8+ memory stem cells in graft-versus-host disease , 2005, Nature Medicine.

[29]  M. Raffeld,et al.  Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer , 1992, The Journal of experimental medicine.

[30]  J. Zúñiga-Pflücker,et al.  In vitro generation of T lymphocytes from embryonic stem cell-derived prehematopoietic progenitors. , 2003, Blood.

[31]  A. Klug,et al.  Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases , 2008, Proceedings of the National Academy of Sciences.

[32]  D. Trono,et al.  Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery , 1998, Journal of Virology.

[33]  E. Elinav,et al.  Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. , 2009, Gastroenterology.

[34]  C. June,et al.  Adoptive T cell therapy for cancer in the clinic. , 2007, The Journal of clinical investigation.

[35]  A. Mackensen,et al.  Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells , 2003, Nature Medicine.

[36]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[37]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[38]  S. Schwarze,et al.  In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.

[39]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[40]  C. Rooney,et al.  Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function. , 2007, Cancer research.

[41]  M. Kay,et al.  In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. , 1993, Science.

[42]  M. Hansmann,et al.  Resistance of mature T cells to oncogene transformation. , 2008, Blood.

[43]  David G. Melvin,et al.  Chromosomal transposition of PiggyBac in mouse embryonic stem cells , 2008, Proceedings of the National Academy of Sciences.

[44]  G. Stamatoyannopoulos,et al.  A capsid-modified adenovirus vector devoid of all viral genes: assessment of transduction and toxicity in human hematopoietic cells. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  C. Lohse,et al.  Questionable Relevance of γδ T Lymphocytes in Renal Cell Carcinoma1 , 2008, The Journal of Immunology.

[46]  Yoshimasa Tanaka,et al.  Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study , 2007, Cancer Immunology, Immunotherapy.

[47]  Jeffrey C. Miller,et al.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases , 2005, Nature.

[48]  Miller Ad,et al.  Improved Retroviral Vectors for Gene Transfer and Expression , 1989 .

[49]  O. Singer,et al.  Tamplicon-7, a Novel T-Lymphotropic Vector Derived from Human Herpesvirus 7 , 1999, Journal of Virology.

[50]  S. Riddell,et al.  The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. , 1990, Journal of immunological methods.

[51]  K. Keyvanfar,et al.  Robust Expansion of Viral Antigen-specific CD4+ and CD8+ T Cells for Adoptive T Cell Therapy Using Gene-modified Activated T Cells as Antigen Presenting Cells , 2006, Journal of immunotherapy.

[52]  M. Tykocinski,et al.  Hierarchical Costimulator Thresholds for Distinct Immune Responses: Application of a Novel Two-Step Fc Fusion Protein Transfer Method1 , 2000, The Journal of Immunology.

[53]  Y. Okamoto,et al.  Combination therapy of in vitro‐expanded natural killer T cells and α‐galactosylceramide‐pulsed antigen‐presenting cells in patients with recurrent head and neck carcinoma , 2009, Cancer science.

[54]  Christof von Kalle,et al.  The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. , 2009, The Journal of clinical investigation.

[55]  E. Shpall,et al.  System Sleeping Beauty the Redirecting Specificity of T-cell Populations for Cd19 Using Cited Articles Citing Articles E-mail Alerts Redirecting Specificity of T-cell Populations for Cd19 Using the Sleeping Beauty System , 2022 .

[56]  R. Lopez.  Human γδ-T cells in adoptive immunotherapy of malignant and infectious diseases , 2002 .

[57]  M. Bonneville,et al.  Self/non‐self discrimination by human γδ T cells: simple solutions for a complex issue? , 2007 .

[58]  Jinjuan Wang,et al.  Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.

[59]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  A. Ganser,et al.  Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. , 2009, The Lancet. Oncology.

[61]  Mitchell Kronenberg,et al.  Toward an understanding of NKT cell biology: progress and paradoxes. , 2005, Annual review of immunology.

[62]  M. Slovak,et al.  Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[63]  C. Dunbar,et al.  Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. , 2003, Blood.

[64]  J. Blattman,et al.  Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. , 2003, Cancer cell.

[65]  E. Pamer,et al.  Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation , 2006, Nature Medicine.

[66]  M. Sadelain,et al.  Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras. , 2008, The Journal of clinical investigation.

[67]  K. Nakagawa,et al.  Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. , 2008, Cytotherapy.

[68]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.

[69]  Daniel G. Miller,et al.  Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. , 2007, Human gene therapy.

[70]  M. Rots,et al.  A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism. , 2003, Virology.

[71]  R. Hagedoorn,et al.  αβ T-Cell Receptor Engineered γδ T Cells Mediate Effective Antileukemic Reactivity , 2006 .

[72]  M. Heřmánková,et al.  A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Y. Furukawa,et al.  Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. , 2008, The Journal of investigative dermatology.

[74]  S. Rosenberg,et al.  High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[75]  K. Irvine,et al.  De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. , 2006, Cancer research.

[76]  D. Baltimore,et al.  Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[77]  F. Guidi,et al.  Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging. , 2000, Cancer research.

[78]  L. Booij,et al.  First clinical experiences with ORG NC 45. , 1980, British journal of anaesthesia.

[79]  M. Todaro,et al.  Efficient Killing of Human Colon Cancer Stem Cells by γδ T Lymphocytes1 , 2009, The Journal of Immunology.

[80]  S. Ekker,et al.  Messenger RNA as a source of transposase for sleeping beauty transposon-mediated correction of hereditary tyrosinemia type I. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[81]  A. Eguchi,et al.  Efficient siRNA Delivery into Primary Cells by Peptide Transduction-dsRNA Binding Domain (PTD-DRBD) Fusion Protein , 2009, Nature Biotechnology.

[82]  W. Janzen,et al.  The use of diversity profiling to characterize chemical modulators of the histone deacetylases. , 2008, Life sciences.

[83]  A. Lawson,et al.  Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain , 2004, The Journal of Immunology.

[84]  M. Connors,et al.  Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. , 1997, Journal of immunology.

[85]  M. Bonneville,et al.  IL-21-Mediated Potentiation of Antitumor Cytolytic and Proinflammatory Responses of Human Vγ9Vδ2 T Cells for Adoptive Immunotherapy1 , 2009, The Journal of Immunology.

[86]  D. Trono,et al.  A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.

[87]  T. Watts,et al.  IL-15-Dependent Induction of 4-1BB Promotes Antigen-Independent CD8 Memory T Cell Survival1 , 2006, The Journal of Immunology.

[88]  S. Rosenberg,et al.  Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy1 , 2005, The Journal of Immunology.

[89]  Y. Hildebrandt,et al.  Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors. , 2004, Experimental hematology.

[90]  P. Rogers,et al.  Expansion of human Vα24+ NKT cells by repeated stimulation with KRN7000 , 2004 .

[91]  J. Orange,et al.  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.

[92]  M. Chamberlain.  Bevacizumab plus irinotecan in recurrent glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  A. Ulph,et al.  An economic evaluation of national parks , 1981 .

[94]  A. Rethwilm.  Foamy virus vectors: an awaited alternative to gammaretro- and lentiviral vectors. , 2007, Current gene therapy.

[95]  J. Sampson,et al.  Selective modification of antigen-specific T cells by RNA electroporation. , 2008, Human gene therapy.

[96]  David Allman,et al.  Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB , 2002, Nature Biotechnology.

[97]  T. Geiger,et al.  Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes. , 2005, Blood.

[98]  Z. Ballas.  The use of 5-azacytidine to establish constitutive interleukin 2-producing clones of the EL4 thymoma. , 1984, Journal of immunology.

[99]  E. Olson,et al.  Deacetylase inhibition promotes the generation and function of regulatory T cells , 2007, Nature Medicine.

[100]  H. Weiner,et al.  What does the future hold for cell-based tolerogenic therapy? , 2007, Nature Reviews Immunology.

[101]  Michel Sadelain,et al.  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor , 2002, Nature Biotechnology.

[102]  Mark M. Davis,et al.  miR-181a Is an Intrinsic Modulator of T Cell Sensitivity and Selection , 2007, Cell.

[103]  M. Tan,et al.  Rapid Immune Recovery and Graft-versus-Host Disease–like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells , 2009, Clinical Cancer Research.

[104]  G. Freeman,et al.  High efficiency gene transfer into murine T cell clones using a retroviral vector. , 1986, Journal of immunology.

[105]  W. Paul,et al.  Spontaneous and Homeostatic Proliferation of CD4 T Cells Are Regulated by Different Mechanisms , 2005, The Journal of Immunology.

[106]  M. Roederer,et al.  T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.

[107]  P. Brauchli,et al.  Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. , 2009, European journal of cancer.

[108]  John J Rossi,et al.  Genetic therapies against HIV , 2007, Nature Biotechnology.

[109]  H. Heslop,et al.  Adoptive T cell therapy of cancer. , 2010, Current opinion in immunology.

[110]  Frederic D Bushman,et al.  Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[111]  U. Bunz.  How Are Alkynes Scrambled? , 2005, Science.

[112]  F. Bushman,et al.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.

[113]  W. Heneine,et al.  Frequent Simian Foamy Virus Infection in Persons Occupationally Exposed to Nonhuman Primates , 2004, Journal of Virology.

[114]  S. Balk,et al.  Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR α‐chain CDR3 loop , 2008, European journal of immunology.

[115]  J. Tolar,et al.  Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. , 2005, Blood.

[116]  G. Bubley,et al.  Loss of IFN-γ Production by Invariant NK T Cells in Advanced Cancer1 , 2001, The Journal of Immunology.

[117]  M. Ferrarini,et al.  Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. , 2002, Trends in immunology.

[118]  Malcolm K. Brenner,et al.  Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.

[119]  S. Sleijfer,et al.  Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo , 2007, Cancer Immunology, Immunotherapy.

[120]  K. Kretschmer,et al.  DNA methylation controls Foxp3 gene expression , 2008, European journal of immunology.

[121]  D. Baltimore,et al.  Targeting lentiviral vectors to specific cell types in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[122]  T. Schumacher,et al.  T-cell-receptor gene therapy , 2002, Nature Reviews Immunology.

[123]  Clelia Di Serio,et al.  Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration , 2006, Nature Biotechnology.

[124]  Y. Okamoto,et al.  A Phase I Study of In vitro Expanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[125]  James M. Allen,et al.  Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors , 2008, Nature Medicine.

[126]  R. Vile,et al.  Virus smuggling, tax evasion and tumor assassination , 2006, Nature Medicine.

[127]  C. Bordignon,et al.  Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. , 2005, Blood.

[128]  L. Fugger,et al.  Redirecting Therapeutic T Cells against Myelin-Specific T Lymphocytes Using a Humanized Myelin Basic Protein-HLA-DR2-ζ Chimeric Receptor1 , 2008, The Journal of Immunology.

[129]  M. Rimbert,et al.  Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma , 2008, Cancer Immunology, Immunotherapy.

[130]  Mary K. Lewinski,et al.  Genome-Wide Analysis of Chromosomal Features Repressing Human Immunodeficiency Virus Transcription , 2005, Journal of Virology.

[131]  Antonio Lanzavecchia,et al.  Understanding the generation and function of memory T cell subsets. , 2005, Current opinion in immunology.

[132]  Yi Li,et al.  Directed evolution of human T-cell receptors with picomolar affinities by phage display , 2005, Nature Biotechnology.

[133]  P. Muranski,et al.  Tumor-specific Th17-polarized cells eradicate large established melanoma. , 2008, Blood.

[134]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[135]  Chien-Fu Hung,et al.  Expression of IL‐15RA or an IL‐15/IL‐15RA fusion on CD8+ T cells modifies adoptively transferred T‐cell function in cis , 2009, European journal of immunology.

[136]  Christopher B Wilson,et al.  Epigenetic control of T-helper-cell differentiation , 2009, Nature Reviews Immunology.

[137]  A. Clarke,et al.  Creating the Costliest Orphan: The Orphan Drug Act in the Development of Ceredase™ , 1992, International Journal of Technology Assessment in Health Care.

[138]  M. Capecchi,et al.  Altering the genome by homologous recombination. , 1989, Science.

[139]  H. Jürgens,et al.  Human γδ T cells as mediators of chimaeric‐receptor redirected anti‐tumour immunity , 2004 .

[140]  A. Lukas,et al.  Mouse Mammary Tumor Virus Integration Site Selection in Human and Mouse Genomes , 2007, Journal of Virology.

[141]  S. Yoon,et al.  Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model , 2009, Cancer Gene Therapy.

[142]  I. Chen,et al.  Lentiviral Vectors--the Promise of Gene Therapy Within Reach? , 1999, Science.

[143]  John R. Mascola,et al.  Gene transfer in humans using a conditionally replicating lentiviral vector , 2006, Proceedings of the National Academy of Sciences.

[144]  M. Sadelain,et al.  The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[145]  A. Miller,et al.  Improved retroviral vectors for gene transfer and expression. , 1989, BioTechniques.

[146]  M. Rollence,et al.  Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein , 1997, Journal of virology.

[147]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[148]  R. Phillips,et al.  Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor , 2008, Nature Medicine.

[149]  G. Zhu,et al.  CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. , 2007, Blood.

[150]  J. Ellis.  Silencing and variegation of gammaretrovirus and lentivirus vectors. , 2005, Human gene therapy.

[151]  C. June,et al.  Extensive Replicative Capacity of Human Central Memory T Cells1 , 2004, The Journal of Immunology.

[152]  D. Russell,et al.  Foamy virus vectors , 1996, Journal of virology.

[153]  B. Moser,et al.  Professional Antigen-Presentation Function by Human γδ T Cells , 2005, Science.

[154]  Kenneth M. Murphy,et al.  Decision making in the immune system: The lineage decisions of helper T cells , 2002, Nature Reviews Immunology.

[155]  Eun-Sung Kim,et al.  Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation , 2006, Nature Medicine.

[156]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[157]  Michel Sadelain,et al.  The promise and potential pitfalls of chimeric antigen receptors. , 2009, Current Opinion in Immunology.

[158]  Y. Mori.  Recent topics related to human herpesvirus 6 cell tropism , 2009, Cellular microbiology.

[159]  Z. Eshhar,et al.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[160]  C. Rooney,et al.  Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. , 2005, Blood.

[161]  Donna Niedzwiecki,et al.  Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer 1 , 2005, The Journal of Immunology.

[162]  D. Largaespada,et al.  Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system , 2005, Nature.

[163]  Robin Holliday,et al.  DNA Modification Mechanisms and Gene Activity during Development , 1996 .

[164]  C. June,et al.  4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy1 , 2007, The Journal of Immunology.

[165]  S. Goff,et al.  Host restriction factors blocking retroviral replication. , 2008, Annual review of genetics.